Is BridgeBio Pharma (BBIO) Pricing Reflect Long Term Potential After 156.5% One Year Surge [Yahoo! Finance]
BridgeBio Pharma, Inc. (BBIO)
Last bridgebio pharma, inc. earnings: 3/2 08:29 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
The stock trades at US$73.99, with returns of 156.5% over 1 year and a very large gain over 3 years, while the year-to-date return of a 5.4% decline and a flat 0.5% return over 30 days suggest sentiment has cooled in the short term. Recent attention around BridgeBio has focused on its progress in developing treatments for genetic diseases and oncology. This has shaped how investors think about the company's future prospects and risk profile. These updates, together with past clinical and regulatory milestones, help explain why the share price has moved so sharply over the longer term. On our simple valuation checklist BridgeBio scores 2 out of 6 . This suggests only a couple of traditional metrics currently point to the shares being undervalued. Next we will compare several valuation approaches and then finish with a broader way of thinking about what the stock might be worth. BridgeBio Pharma scores just 2/6 on our valuation checks. See what other red flags we found in the ful
Show less
Read more
Impact Snapshot
Event Time:
BBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BBIO alerts
High impacting BridgeBio Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
BBIO
News
- BridgeBio Pharma (NASDAQ:BBIO) had its "buy" rating reaffirmed by analysts at Cowen Inc.MarketBeat
- BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- BridgeBio Pharma Investor Update: PROPEL 3 “Last Visit” Set as Infigratinib Phase 3 Readout Nears [Yahoo! Finance]Yahoo! Finance
- BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by analysts at Truist Financial Corporation from $80.00 to $86.00. They now have a "buy" rating on the stock.MarketBeat
- BridgeBio Pharma (NASDAQ:BBIO) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $96.00 price target on the stock.MarketBeat
BBIO
Earnings
- 10/29/25 - Miss
BBIO
Sec Filings
- 1/12/26 - Form 8-K
- 1/8/26 - Form 144
- 1/8/26 - Form 144
- BBIO's page on the SEC website